AHR and myeloid sarcoma: Given its ability to inhibit NF-κB signaling and induce an AhR-like functional signature, DMF supplementation in MS patients or addition of DMF ex vivo during differentiation can reverse MS monocytes’ proinflammatory signature, leading to more powerful tolDCs.